Steminent Biotherapeutics Inc is a Taiwan-based trading company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms. The Company's main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington's disease, acute ischemic stroke, acute inflammatory indications and other diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
18/09/26	NT$152.00	-3.18%	2,800,643
17/09/26	NT$157.00	+14.18%	3,952,993
16/09/26	NT$137.50	+5.77%	2,062,122
15/09/26	NT$130.00	+14.54%	2,035,793
14/09/26	NT$113.50	-0.87%	870,363

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 18/09/2026			5-day change	1st Jan Change
152.00 ^TWD	-3.18%		+26.14%	+152.91%

08-13	Steminent Biotherapeutics Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
03-31	Steminent Biotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	6.26B 197M 172M 162M 147M 276M 18.88B 277M 1.94B 749M 9.6B 739M 723M 30.88B	P/E 2024	-8.1x	P/E 2025	-20.4x
Enterprise Value	5.84B 183M 160M 151M 137M 257M 17.59B 258M 1.81B 698M 8.94B 689M 673M 28.78B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	58.85%	Yield 2024 *	-	Yield 2025	-

08-13	Steminent Biotherapeutics Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
03-31	Steminent Biotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-18	Steminent Biotherapeutics Inc. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
24/04/25	Steminent Biotherapeutics Inc. to Showcase Breakthrough MSC-Based Therapy for Spinocerebellar Ataxia at WODC USA and ISCT 2025	CI

1 day	-3.18%
1 week	+26.14%
Current month	+97.15%
1 month	+90.24%
3 months	+82.69%
6 months	+70.79%
Current year	+152.91%

Steminent Biotherapeutics Inc. Stock

Stocks

7729

TW0007729006

Biotechnology & Medical Research

Valuation: Steminent Biotherapeutics Inc.

Chart: Steminent Biotherapeutics Inc.

Latest news: Steminent Biotherapeutics Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Steminent Biotherapeutics Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	108.5	169.5
1 month	74.6	169.5
Current year	51.4	169.5
1 year	37.85	169.5
3 years	15.25	169.5
5 years	15.25	169.5
10 years	15.25	169.5

Manager	Title	Age	Since
Ling Mei Wang CEO	Chief Executive Officer	-	26/11/2018
I Chih Lo DFI	Director of Finance/CFO	-	15/09/2021
Ching Huai Ko IRC	Investor Relations Contact	-	01/10/2023

Director	Title	Age	Since
Chih Hung Yeh BRD	Director/Board Member	54	08/12/2021
Cheng Chi Chiang BRD	Director/Board Member	-	15/09/2020
Ling Mei Wang CHM	Chairman	-	26/01/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STEMINENT BIOTHERAPEUTICS INC.	-3.18%	+26.14%	+280.48%	-	397M
LONZA GROUP AG	+0.11%	+1.98%	-0.04%	+9.69%	46.18B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+40.07%	+27.26%	44.35B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+322.27%	+517.36%	42.21B
BEONE MEDICINES AG	-0.74%	+1.25%	+2.32%	+67.94%	40.19B
CELLTRION, INC.	-0.50%	-0.77%	+11.86%	+40.41%	29.83B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+21.99%	+124.21%	17.17B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.7B
EUROFINS SCIENTIFIC SE	-0.57%	+7.78%	+21.76%	+38.08%	15.32B
ICON PUBLIC LIMITED COMPANY	-3.28%	-3.07%	-8.54%	-37.61%	13.09B
Average	-1.38%	+4.89%	+76.91%	+98.42%	26.44B
Weighted average by Cap.	-1.12%	+1.68%	+66.48%	+119.41%

	2024	2025
Net sales	-	-
Net income	-159M -4.99M -4.35M -4.11M -3.73M -6.99M -479M -7.02M -49.19M -18.98M -243M -18.74M -18.32M -783M	-174M -5.47M -4.77M -4.5M -4.09M -7.66M -525M -7.69M -53.93M -20.81M -267M -20.54M -20.08M -858M
Net Debt	-153M -4.81M -4.2M -3.96M -3.6M -6.74M -462M -6.77M -47.48M -18.32M -235M -18.08M -17.68M -756M	-426M -13.38M -11.67M -11.02M -10M -18.74M -1.28B -18.82M -132M -50.92M -653M -50.26M -49.14M -2.1B